Concurrent use or receipt of a strong CYPA inducer within  days prior to randomization or a strong CYPA inhibitor within  days prior to randomization (see Table )
Patients may not have received a strong CYPA inducer within  days prior to registration nor a strong CYPA inhibitor within  days prior to registration
Concomitant use of medications known to have strong inhibition or induction of CYPA enzymes is discouraged and should be discussed with the study principal investigator (PI); note that systemic corticosteroids (e.g., dexamethasone is a CYPA inducer) are not allowed; inhaled corticosteroids are allowed
Use of potent inhibitor or inducer of CYPA/A within  days of planned study treatment or expected requirement for use of such a drug during study
Use of a potent inhibitor or inducer of drug transporters or conjugating enzymes within  days prior to planned study treatment or expected requirement for use of such a drug during study
Is receiving concomitant treatment with a strong inhibitor or inducer of CYPA/.
Require continued treatment with a medication that is known to be a strong inducer of CYPA.
Use of a strong inhibitor or inducer of cytochrome P A (CYPA) within  days prior to the start of study therapy or expected requirement for use of a strong CYPA inhibitor or inducer during study therapy.
Treatment with a strong CYPA inhibitor or a strong cytochrome P inducer within the last  weeks
Intake of St. John's wort or hyperforin (potent cytochrome P [CYP] A enzyme inducer) or grapefruit juice (potent CYPA enzyme inhibitor) within  days prior to initiation of study treatment
Concurrent use of any medications or substances (e.g. herbal supplement or food) known to be a strong inhibitor or strong inducer of CYPA.\r\n* Although corticosteroids are considered to be strong inducers of CYPA, physiologic replacement doses of corticosteroids =<  mg daily prednisone or equivalent are allowed.
The following foods/supplements are prohibited at least  days prior to initiation of and during study treatment:\r\n* St. Johns wort or hyperforin (potent cytochrome P CYPA enzyme inducer)\r\n* Grapefruit juice (potent cytochrome P CYPA enzyme inhibitor)
Patients who require therapy with a concomitant medication that is a strong inhibitor or strong inducer of CYPA.
The patient has taken a medication known to be a potent inducer of CYPA, CYPC, or CYPA within  weeks prior to the first dose of study drug
The patient has taken a medication known to be a potent inhibitor of CYPA, CYPC, or CYPA within  weeks prior to the first dose of study drug
Taken a strong inhibitor or inducer of CYPA within  days prior to enrollment
The following foods/supplements are prohibited at least  days prior to initiation of and during study treatment: () St. Johns wort or hyperforin (potent CYPA enzyme inducer) () grapefruit juice (potent cytochrome P CYPA enzyme inhibitor)
Subjects who are required to use a medication classified as a strong CYPA inducer of inhibitor
Requires treatment with a strong CYPA inhibitor/inducer
Patient who is on strong inducer/inhibitor of CYPA needs to be off the medication prior to treatment initiation unless it is medically necessary for the patient
The following foods/supplements are prohibited at least  days prior to initiation of and during study treatment:\r\n* St. Johns wort or hyperforin (potent cytochrome P CYPA enzyme inducer)\r\n* Grapefruit juice (potent cytochrome P CYPA enzyme inhibitor)
Taking a strong inhibitor or inducer of cytochrome P; intermediate inhibitors are allowed if deemed medically necessary
Has taken a medication that is a potent inhibitor or inducer of cytochrome P A (CYPA) within -week prior to screening.
Consumption of any concomitant nutritional, herbal supplements, and antioxidants should be taken under the discretion of the investigator; the following foods/supplements are prohibited at least  days prior to initiation of and during study treatment:\r\n* St. Johns wort or hyperforin (potent CYPA enzyme inducer)\r\n* Grapefruit juice (potent cytochrome P CYPA enzyme inhibitor)
Patient who are required to take a strong CYPA inducer are excluded from the study
Has been treated with a cytochrome P A (CYPA) strong inhibitor or inducer within  days of enrollment
A strong or moderate CYPA inhibitor or inducer within  days
Is receiving concomitant treatment with a strong inhibitor or inducer of CYPA/.
Concurrent use of a strong cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitor or inducer; these medications should be discontinued or switched to a different medication with a weaker CYPA interaction prior to enrollment into the study; if patients need to continue the same medication(s), they are excluded from the study
Received a potent CYPA inhibitor within  days or potent CYPA inducer within  weeks prior to first dose of AP.
Administration of a strong or moderate CYPA inhibitor or inducer =<  days prior to registration
Treatment with any drug(s) known to be an inhibitor or inducer of cytochrome P (CYP)C, CYPA, CYPC, and CYPE, within  days of the date of first administration of study drug
Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYPA pathway or P-glycoprotein activity
Less than  weeks since use of a medication or ingestion of an agent, beverage, or food that is a potent inhibitor or inducer of the CYPA pathway or P-glycoprotein activity
Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYPA pathway or P-glycoprotein activity
Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYPA pathway or P-glycoprotein activity
Treatment with a moderate or strong cytochrome P A (CYPA) inhibitor or inducer within  days prior to\r\nfirst dose of venetoclax or need for treatment with a strong CYPA inhibitor or inducer during the period or the study; patients who have a need for treatment with a moderate CYPA inhibitor or inducer during venetoclax dose escalation will also be excluded
Concurrent use of any medications or substances (e.g. herbal supplement or food) known to be a strong inhibitor or strong inducer of CYPA
Subject has received a strong and/or moderate CYPA inducer within  days prior to the initiation of study treatment.
Requires treatment with a strong CYPA inhibitor/inducer.
Receipt of a strong CYPA inducer within  days prior to cycle  day  or a strong CYPA inhibitor within  days prior to cycle  day  (Table )
Intake of St. John's wort or hyperforin (potent cytochrome P [CYP] A enzyme inducer) or grapefruit juice (potent CYPA enzyme inhibitor) within  days preceding the start of study treatment to the end of treatment
Use of strong CYPA inducer
Patients must not have continued requirement for therapy with a strong cytochrome P A/ (CYPA/) inhibitor or inducer
Use of a strong CYPA inducer or inhibitor, or strong CYPC inducer or inhibitor within  elimination half-lives of the inhibitor or inducer prior to first dose of study treatment
Patients requiring treatment with a strong CYPA inhibitor or inducer Additional exclusion criteria for PDR/Panobinostat-
Patients requiring a strong inhibitor or inducer of CYPA
Use of potent cytochrome P A (CYPA) inducer within one week of pacritinib initiation
Requires ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome A (CYPA) enzymes
Use of a strong CYPC inducer or inhibitor within three elimination half-lives of the inducer or inhibitor prior to the start of study treatment.
The following foods/supplements are prohibited at least  days prior to initiation of\r\nand during study treatment:\r\n* St. Johns wort or hyperforin (potent cytochrome P family , subfamily A, polypeptide  [CYPA] enzyme inducer)\r\n* Grapefruit juice (potent cytochrome P CYPA enzyme inhibitor)
Use of any strong CYPA inducer such as rifampin, St John's Wort, or other herbal preparations that contain any strong CYPA inducer (see Table  )  days before the first dose of study drug or during the study
Concurrent administration of crizotinib and a strong inhibitor or inducer of cytochrome P, family , subfamily A (CYPA) is not permitted; many over-the-counter and dietary supplements also inhibit or induce CYPA and thus are prohibited
St. John's wort or hyperforin (potent cytochrome P CYPA enzyme inducer)
Use of strong cytochrome P A (CYPA) inducer within  weeks prior to the first dose of MMB
Concurrent therapy with a potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inducer or inhibitor; subjects may enter screening when therapy with the potent inhibitor or inducer is completed and may begin study treatment after  week or  half-lives, whichever is longer
Administration or possibility of initiating or continuing any treatment with any known Cytochrome P A (CYPA) and CYPC enzyme and P-glycoprotein altering drugs (inducer or inhibitor) or non drug agents within  days prior to dosing and during the primary objective phase
Patient has received any of the following agents within  days prior to study day  and/or are planned to receive throughout the duration of the study: opioid antagonist and mixed agonist/antagonist (e.g. pentazocine, buprenorphine, nalbuphine, naloxone/naloxone combinations, naltrexone/naltrexone combinations, methylnaltrexone, alvimopan), a strong cytochrome P family  subfamily A polypeptide  (CYPA) and/or P-glycoprotein  (P-gp) inhibitor, a moderate CYPA and/or P-gp inhibitor, and/or a strong CYPA inducer
Currently using select CYPD inhibitor or inducer medications
Current use of strong CYPA inducers or inhibitors\r\n* NOTE: patients may be eligible if they transition to an alternative agent or are able to stop CYPA inducer or inhibitor
Subjects on a potent CYPA inhibitor or CPYA inducer who cannot be changed to another medication are excluded
Less than  weeks or  plasma half-lives (whichever is greater) since last use of a medication or ingestion of an agent, beverage, or food that is a potent inhibitor or inducer of the cytochrome P (CYP)A or CYPC pathways (patients should discontinue taking any regularly-taken medication that is a potent inhibitor or inducer of the CYPA or CYPC pathways)
Participants taking any drug that is a strong inhibitor or inducer of the CYPA enzyme within at least  weeks before the start of study drug and during the conduct of the study unless there is an emergent or life-threatening medical condition that requires it
